睿知中国医院研究地图
候选清单

正在招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 7 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 7

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
  2. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
  3. 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
  4. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  5. 研究中心北京协和医院Peking Union Medical College Hospital北京医院页面
  6. 研究中心上海市胸科医院Shanghai Chest Hospital上海医院页面
  7. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07476287,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed T-SCLC. Participant must have had a prior diagnosis of NSCLC with EGFR mutation which transformed to SCLC following the treatment with TKI(s).

    入选标准第 2 条

  3. Unresolved toxicity from prior anti-tumor therapy that has not recovered to Grade ≤1 per NCI CTCAE v5.0 (except alopecia or irreversible toxicities deemed stable)

    排除标准第 5 条

  4. Eastern Cooperative Oncology Group performance status of 0 or 1.

    入选标准第 6 条

  5. Have at least one measurable lesion as the target lesion based on RECIST v1.1.

    入选标准第 4 条

  6. History of another malignancy (other than NSCLC) within 3 years prior to first dose, except for malignancies with negligible risk of metastasis or death (eg, adequately treated carcinoma in situ, nonmelanoma skin cancer)

    排除标准第 4 条

  7. Pregnant or breastfeeding participants, or unwillingness to comply with contraception requirements

    排除标准第 28 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07476287,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Male or female participants aged ≥18 years at the time of informed consent.
  2. Histologically or cytologically confirmed T-SCLC. Participant must have had a prior diagnosis of NSCLC with EGFR mutation which transformed to SCLC following the treatment with TKI(s).
  3. Participants have not received systemic therapy for T-SCLC.
  4. Have at least one measurable lesion as the target lesion based on RECIST v1.1.
  5. Have sufficient tumor tissue from the diagnosis of transformed SCLC available.
  6. Eastern Cooperative Oncology Group performance status of 0 or 1.
  7. Have a minimum life expectancy of >12 weeks.
  8. Clinical laboratory values at screening within acceptable limits, as defined in the protocol, including: 1) Hematology, 2) Liver function and 3) Renal function.

排除标准:Exclusion Criteria:

  1. Active or untreated CNS disease, including brain, brainstem, spinal cord, or meningeal metastases. Participants with definitively treated, clinically stable brain metastases may be eligible per protocol criteria. Participants with untreated asymptomatic brain metastases of longest diameter <1 cm are permitted if all of the following criteria are met: absence of neurological symptoms, no need for corticosteroids, and brain metastasis has no evidence of edema or hemorrhagic features.
  2. Leptomeningeal disease
  3. Clinically significant risk of hemorrhage or fistula, including tumor necrosis/cavitation, invasion or compression of major blood vessels, airways, or critical organs, or risk of tracheoesophageal or pleuroesophageal fistula
  4. History of another malignancy (other than NSCLC) within 3 years prior to first dose, except for malignancies with negligible risk of metastasis or death (eg, adequately treated carcinoma in situ, nonmelanoma skin cancer)
  5. Unresolved toxicity from prior anti-tumor therapy that has not recovered to Grade ≤1 per NCI CTCAE v5.0 (except alopecia or irreversible toxicities deemed stable)
  6. History of allogeneic organ or hematopoietic stem cell transplantation
  7. Active autoimmune disease requiring systemic treatment within the past 2 years (Stable replacement therapy and selected low-risk autoimmune conditions are permitted per protocol)
  8. Interstitial lung disease (ILD), pneumonitis, or significant pulmonary disease, including:
  9. Prior or current non-infectious pneumonitis requiring systemic therapy
  10. DLCO <50% predicted
  11. Severe asthma, COPD, pulmonary embolism, or autoimmune lung involvement
  12. Uncontrolled or clinically significant cardiovascular, cerebrovascular, metabolic, hepatic, or renal disease within 6 months prior to first dose
  13. Baseline QTcF >480 msec
  14. Major surgery or severe trauma within 4 weeks prior to first dose, or planned major surgery during the study
  15. Clinically significant pleural effusion, pericardial effusion, or ascites requiring repeated drainage
  16. History of significant bleeding disorders or recent major bleeding events
  17. Clinically significant gastrointestinal conditions, including recent perforation, fistula, obstruction, or active bleeding
  18. Active, uncontrolled, or symptomatic infection, including:
  19. Active TB
  20. Active hepatitis B or C
  21. Uncontrolled HIV infection
  22. History of immunodeficiency
  23. Severe hypersensitivity or allergic reactions to study intervention components or monoclonal antibodies
  24. Psychiatric illness or medical condition, including recent suicidal ideation or behavior, that may increase risk or interfere with study participation
  25. Prior anti-angiogenic therapy or other prohibited anti-tumor or immunomodulatory therapies per protocol-specified washout periods
  26. Use of prohibited concomitant medications, including high-dose systemic corticosteroids, certain anticoagulants, or live vaccines within protocol-specified timeframes
  27. Recent participation in another investigational study (within 30 days or 5 half-lives, whichever is longer)
  28. Pregnant or breastfeeding participants, or unwillingness to comply with contraception requirements

引自 ClinicalTrials.gov, NCT07476287, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07476287,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07476287